Issues related to 340b drug pricing program; Expiring healthcare extenders
2025 · 4th Quarter (Oct 1 - Dec 31)
GENENTECH USA, INC.
Filed by AVENUE SOLUTIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- AVENUE SOLUTIONS
- Client
- GENENTECH USA, INC.
- Filing UUID
- 6d808c13-9b28-4af4-a51b-f7257586b017
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act
Literal federal measure citations: H.R. 4299, H.R. 1492, H.R. 1672
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.